Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors
Authors
Keywords
-
Journal
Dermatology and Therapy
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-09-02
DOI
10.1007/s13555-021-00596-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- POS1042 EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, COMPARED WITH PLACEBO AND APREMILAST IN MODERATE TO SEVERE PLAQUE PSORIASIS: RESULTS FROM THE PHASE 3 POETYK PSO-1 STUDY
- (2021) A. Armstrong et al. ANNALS OF THE RHEUMATIC DISEASES
- JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors
- (2020) Miguel Nogueira et al. DRUGS
- Safety of Janus Kinase Inhibitors in Patients with Inflammatory Bowel Diseases or Other Immune-mediated Diseases: a Systematic Review and Meta-Analysis
- (2020) Pablo Olivera et al. GASTROENTEROLOGY
- Emerging systemic drugs in the treatment of plaque psoriasis
- (2020) Esther A. Balogh et al. EXPERT OPINION ON EMERGING DRUGS
- Translating JAKs to Jakinibs
- (2020) Massimo Gadina et al. JOURNAL OF IMMUNOLOGY
- Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I–III Clinical Trials
- (2019) Ben Klünder et al. CLINICAL PHARMACOKINETICS
- Population pharmacokinetics of tofacitinib in patients with psoriatic arthritis
- (2019) Rujia Xie et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165
- (2019) Stephen T. Wrobleski et al. JOURNAL OF MEDICINAL CHEMISTRY
- Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain
- (2019) James R. Burke et al. Science Translational Medicine
- Preferential Inhibition of JAK1 Relative to JAK3 by Upadacitinib: Exposure‐Response Analyses of Ex Vivo Data From 2 Phase 1 Clinical Trials and Comparison to Tofacitinib
- (2019) Mohamed‐Eslam F. Mohamed et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Targeting the Janus Kinase Family in Autoimmune Skin Diseases
- (2019) Michael D. Howell et al. Frontiers in Immunology
- Systemic Treatment of Psoriasis with JAK Inhibitors: A Review
- (2019) Amanda Kvist-Hansen et al. Dermatology and Therapy
- The Interleukin-23/Interleukin-17 Axis Links Adaptive and Innate Immunity in Psoriasis
- (2018) Michael P. Schön et al. Frontiers in Immunology
- Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis
- (2018) Kim Papp et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
- (2017) Daniella M. Schwartz et al. NATURE REVIEWS DRUG DISCOVERY
- The emerging safety profile of JAK inhibitors in rheumatic disease
- (2017) Kevin L. Winthrop Nature Reviews Rheumatology
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started